Skip to content
Menu

Ampio Pharmaceuticals, Inc. AMPE

Full chart Compare
Set alert

Price alert · AMPE

All alert types
0.18 USD 0.00 (+0.00%)

Regular-session close

0.0052 Day range 0.0052
0.0052 52-week range 0.6435
YTD
+3,421.15%
1 year
+3,421.15%

Fundamental scorecard

7 of 25 checks passed on AMPE’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Dec 31, 2023.

Value 1 of 5

  • Failed:P/E below its own 5-year median No profit over the last 12 months, so no P/E.
  • Failed:P/E under 20 No profit over the last 12 months, so no P/E.
  • Failed:Price to sales below its own 5-year median Not enough data to decide.
  • Passed:Price to book below its own 5-year median Price to book 0.1 against a 5-year median of 4.2.
  • Failed:Free cash flow yield above 4% Free cash flow of -8.56M is -4119.6% of the market value.

Growth 1 of 5

  • No data:Revenue grew over the last year Not enough data to decide.
  • No data:Revenue grew more than 5% a year over five years Not enough data to decide.
  • Passed:Earnings per share grew over the last year EPS -11.01 against -29.30 in the 12 months before.
  • Failed:Earnings per share grew more than 5% a year over five years EPS -36.00 in FY 2018, -10.66 in FY 2023.
  • No data:Analysts expect higher earnings per share over the next year No analyst estimate.

Profitability 0 of 5

  • Failed:Profitable over the last year Net income of -8.63M over the last 12 months.
  • Failed:Profitable in each of the last five fiscal years A profit in 0 of the last 5 fiscal years.
  • Failed:Return on equity above 15% Return on equity of -114.0%.
  • No data:Net margin above its 5-year average Not enough data to decide.
  • Failed:Free cash flow is at least 80% of net income No profit over the last 12 months to compare with.

Financial health 5 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 5.74M against short-term liabilities of 2.38M.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 5.74M against long-term liabilities of 0.
  • Passed:Net debt under 40% of equity More cash than debt: 4.09M of cash against 0 of debt.
  • Passed:Operating cash flow covers at least 20% of debt The company has no debt.
  • Passed:Operating profit covers interest at least 3 times The company has no debt.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What AMPE owns and owes, as of Dec 31, 2023

Short term and long term

Balance sheet · 5.74M of assets

Debt, equity and cash by year

Now: 4.09M more cash than debt

Fiscal years. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

-63.76 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

3 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

Valuation

P/E -0.2×
P/S 0.0×
P/B 0.5×
P/FCF -0.2×
EV/EBITDA 0.3×
EV/Sales 0.0×
FCF Yield -516.4%

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
ROE -256.9%
ROIC -252.5%
ROA -150.5%

Growth (YoY)

Revenue 0.0%
Operating Income 53.3%
EPS (diluted) 63.6%
Free Cash Flow 59.5%

Financial Health

Current Ratio 2.4×
Quick Ratio 2.4×
Debt / Equity 0.1×
Net Debt / EBITDA 0.4×
Interest Coverage 0.0×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2023-12-31